Table 3.
Histological and ELISA Assessments of Nonbiofunctionalized Polymers at 6 Weeks
| PDO (n=15) | PU (n=18) | PHBVV (n=11) | Global p-value | |
|---|---|---|---|---|
| vWF (%) | 100 | 100 | 100 | ns |
| SMA (%) | 96 (±9) | 59 (±35) | 89 (±22) | 0.0006 |
| ED1 (%) | 92 (±14) | 92 (±12) | 71 (±24) | 0.0038 |
| ED2 (%) | 50 (±13) | 66 (±19) | 37 (±17.5) | 0.0002 |
| ED2/ED1 (%) | 55 (±14) | 72.5 (±19) | 58 (±30) | 0.0414 |
| Granuloma, n (%) | 0 | 4 (22) | 0 | ns |
| IL-6 (pg/mL) | 305 (±195) | 163 (±143) | 6 (±9.85) | <0.0001 |
| MCP 1 (pg/mL) | 25,073 (±10,736) | 13,009 (±7552) | 5782 (±6491) | <0.0001 |
| iNOS (ng/mL) | 2.56 (±4.06) | 2.58 (±2.88) | 1.40 (±1.01) | ns |
| IL-10 (pg/mL) | 2186 (±1279) | 1309 (±1177) | 807 (±613) | 0.015 |
Data were analyzed by analysis of variance or analysis of variance on ranks (when appropriate) for quantitative variables; exact Fisher test for qualitative variables; and pairwise comparisons with Tukey correction for multiple comparisons.
±values in paranthesis represent standard deviation.
ELISA, enzyme-linked immunosorbent assay; IL, interleukin; iNOS, inducible NO synthase; ns, not significant; SMA, smooth muscle actin; vWF, von Willebrand factor.